A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention
暂无分享,去创建一个
Taeseung Lee | A. Han | S. Min | Hyunmin Ko | Yang-Jin Park | J. Gwon | Joongyub Lee | I. Jung | W. Yun | Yong-Pil Cho | J. Kang | Sang-Su Lee | Suk-Won Song | Suk-Won Song
[1] Manesh R. Patel,et al. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD , 2021, Circulation.
[2] C. Mena-Hurtado,et al. Real-World Antithrombotic Treatment Variability in Patients Undergoing Peripheral Vascular Intervention: Insights from the VQI Registry. , 2021, American heart journal.
[3] Sonia S Anand,et al. Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial. , 2021, Journal of the American College of Cardiology.
[4] Manesh R. Patel,et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. , 2020, The New England journal of medicine.
[5] Tracy Y. Wang,et al. Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. , 2020, Journal of the American College of Cardiology.
[6] L. Mazzolai,et al. ESVM Guideline on peripheral arterial disease , 2019 .
[7] J. Mao,et al. Local infiltration with cocktail analgesics during 2 level lumbar spinal fusion surgery , 2019, Medicine.
[8] P. Dall,et al. Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease , 2018, PloS one.
[9] A Ross Naylor,et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.
[10] P. Thompson,et al. Review of aspirin and clopidogrel resistance in peripheral arterial disease , 2017, Journal of vascular surgery.
[11] S. Min,et al. SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial , 2017, Trials.
[12] S. Johansson,et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study , 2017, Journal of vascular surgery.
[13] L. Fleisher,et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.
[14] Freya J. I. Fowkes,et al. Peripheral artery disease: epidemiology and global perspectives , 2017, Nature Reviews Cardiology.
[15] T. Oh,et al. Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes. , 2017, Atherosclerosis.
[16] J. Coresh,et al. Lower Extremity Peripheral Artery Disease and Quality of Life Among Older Individuals in the Community , 2017, Journal of the American Heart Association.
[17] S. Johansson,et al. Long-Term Healthcare Costs of Patients with Symptomatic Peripheral Artery Disease with and without a History of Atherosclerotic Disease: Results from a Swedish Nationwide Study , 2016 .
[18] Deepak L. Bhatt,et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.
[19] Xinghuan Wang,et al. Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection , 2020, Medicine.
[20] B. Modarai,et al. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis , 2015, PloS one.
[21] Yongquan Gu,et al. Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results , 2015, Chinese medical journal.
[22] K. Urasawa,et al. Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study , 2013, Circulation.
[23] Wei Wang,et al. Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. , 2013, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[24] D. Sobieraj,et al. Dosing frequency and medication adherence in chronic disease. , 2012, Journal of managed care pharmacy : JMCP.
[25] C. Claussen,et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial , 2012, European Radiology.
[26] Ying Su,et al. Sarpogrelate inhibits the expression of ICAM-1 and monocyte–endothelial adhesion induced by high glucose in human endothelial cells , 2012, Molecular and Cellular Biochemistry.
[27] E. Miyaoka,et al. Comparisons of Test Statistics for Noninferiority Test for the Difference between Two Independent Binominal Proportions , 2010 .
[28] M. Nobuyoshi,et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. , 2009, Journal of the American College of Cardiology.
[29] M. Kitakaze,et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. , 2008, Journal of vascular surgery.
[30] S. Doggrell. Sarpogrelate: cardiovascular and renal clinical potential , 2004, Expert opinion on investigational drugs.
[31] M. Fujita,et al. Sarpogrelate treatment reduces restenosis after coronary stenting. , 2003, American heart journal.
[32] L. Sharma,et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. , 2001, JAMA.
[33] J. Werner,et al. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. , 2001, The Annals of thoracic surgery.
[34] N. Sobol,et al. PRELIMINARY RESULTS , 2004 .